The purpose of this study is to investigate whether entecavir treatment increases the
incidence of lactic acidosis compared to another nucleoside/nucleotide reverse transcriptase
inhibitors (NRTI), lamivudine, and/or no NRTI treatment, in patients with cirrhosis or
hepatic failure whose Model for End stage Liver Disease (MELD) scores are over 18.